Kenvue Inc. (KVUE)

Rating: HOLD

HOLD (5-tier) · income compounder · conviction: medium

EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).

Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-26. Each chart below sits with the part of the thesis it evidences.

General research for a skeptical institutional reader. Not personalised investment advice; no position sizing or trade instructions. Figures as of the analysis date; verify before acting.

Investment Committee Summary

📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.

Rating Bridge

Rating = HOLD because:

• Probability-weighted scenario value implies -9% vs spot
• Monte Carlo median implies -17% vs spot
• DCF fair value implies -26% vs spot — but this is terminal-value sensitive (exit-multiple $15 vs Gordon $21, 43% apart), so it carries less weight
• Bear case (Structural — Private-Label / Brand Erosion) downside is -62% vs spot
• Net: reward/risk of 0.2× is not asymmetric enough for a Buy and not impaired enough for a Sell — hence Hold.

Investment Thesis

At $19.11 on ~16.6x forward earnings, the market prices Kenvue as an average consumer-staples franchise: dependable dividend, low-single-digit organic growth, no re-rating. The engine broadly agrees rather than dissents. The triangulated fair value sits near $18.40, a shade below spot, so the rating is HOLD. The probability-weighted target is dragged down by two features the multiple alone hides. First, the Monte Carlo assigns 38% weight to structural or recessionary paths, where private-label share gains compress both organic growth and the mid-50s gross margin. Second, the independent capex-bridge DCF lands at roughly $15 per share, well under the market multiple, flagging that the current price already discounts steady execution. Base-case earnings power of about $1.17 supports the mid-cycle target only if pricing holds and beauty recovers. Net debt of $7.6B against a covered but tightly financed dividend leaves little slack. The single most damaging risk is durable private-label substitution in core over-the-counter and skin-care lines, which would erode volume and pricing at once and validate the structural path below the 52-week low.

The dashboard below is the whole argument on one page: spot ($20) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The highest-probability bear mechanism is not a crash but slow structural erosion. Kenvue's brands compete against retailer private label in categories where the value gap has narrowed and shoppers have grown willing to trade down. If organic growth drifts toward zero while input and promotional costs keep gross margin under the high-50s, mid-cycle earnings never materialise. The market then re-rates a low-growth, leveraged staples name toward the low teens on the multiple, not the high teens. With $7.6B of net debt and a dividend that already absorbs most free cash flow, there is little room to defend the payout through a downturn. Earnings and the multiple compress together, and the target settles below the 52-week low.

Key Debate

P/E Multiple explains 54% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2025Q2): management +0.29 vs analyst floor +0.09 → delta +0.21 (n=12 mgmt / 7 Q&A; 14th pctile across the S&P book, z -1.1).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 1000 articles): avg ticker sentiment +0.12 (bullish 14% / bearish 4%)

Scenario Analysis

The tree runs from a structural 'Structural — Private-Label / Brand Erosion' downside ($8) to a 'Bull — Defensive Re-Rate' bull case ($29); the probability-weighted blend (PWEV $18) is -9% versus spot.

Scenario rationale — what each probability buys (the driver path behind every target):

• Structural — Private-Label / Brand Erosion (20%, $8). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 8.54; probability: 0.2.
• Consumer / Input Recession (18%, $14). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising. Drivers — implied_target: 15.17; probability: 0.18.
• Base — Pricing-Led Organic Growth (34%, $20). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns. Drivers — implied_target: 19.63; probability: 0.34.
• Growth — Premium Innovation + EM (20%, $24). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 24.78; probability: 0.2.
• Bull — Defensive Re-Rate (8%, $29). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets. Drivers — implied_target: 29.15; probability: 0.08.

Valuation Triangulation

Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Rating vs blend — the key debate. The rating tracks the multiple-discipline fair value (Monte Carlo $16 + scenario PWEV $18, ≈ spot); the weighted blend $17 (-15%) sits below it because the cash-flow DCF ($15) is materially more conservative than the market multiple. Whether the current multiple is justified is the central question for this name — and the principal downside risk to the rating.

Monte Carlo — the distribution, not a point

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $16 and 33% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (54% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 7.5%, 14x terminal FCF multiple → $15. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median forward multiple (P/E 18.990000000000002x) implies $22. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.

Across all anchors the spread is 85% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Consumer Staples — Household

This name sits in the Consumer Staples — Household as a household_personal. branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: PG (household_personal) · CL (household_personal) · KVUE (household_personal) · KMB (household_personal) · EL (household_personal) · CHD (household_personal) · CLX (household_personal)

Mapping note: name-level 'Structural — Private-Label / Brand Erosion' (20%) + 'Consumer / Input Recession' (18%) map to cluster Structural — Private-Label / Brand Erosion (38%); name-level 'Growth — Premium Innovation + EM' (20%) + 'Bull — Defensive Re-Rate' (8%) map to cluster Upside — Premium Innovation / EM (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Structural — Private-Label / Brand Erosion () — this name implies 38% vs the cluster house view of 38% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The staples_household cycle is the shared macro driver. Driver — branded HPC pricing power + organic volume + input costs Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 7.5% · Σ PV(FCF) $10B + PV(terminal) $26B = EV $36B; + net cash → equity $28B ÷ diluted shares 1.93B = $15/share (exit-multiple terminal).

• Gordon (perpetuity-growth) terminal at 2.5% → $21/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 17% vs WACC 8% → above WACC — the build is value-creative.

Peer set

Peer-median fwd P/E → $22; EV/Rev → $8.

Weighted fair-value math

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Household & Personal Care multiple (AI re-rating) (base 16x)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 0.9% of revenue; cash conversion (OCF/NI) 150% — cash-backed.

Catalyst Calendar

• 2026-02-19 (~-139d) — FY results with post-spin standalone margin and cost-program update (authored)
• 2026-07-15 (~7d) — Tylenol (acetaminophen) product-liability litigation procedural milestone (authored)
• 2026-08-06 (~29d) — Quarterly earnings — est. EPS $0.32 (AV EARNINGS_CALENDAR)
• 2027-03-15 (~250d) — Skin Health & Beauty (Neutrogena/Aveeno) turnaround progress checkpoint (authored)

Forecast Track Record

• EPS surprise: beat 87.5% of the last 8 quarters; average surprise +9.9%.

Competitive Moat

Narrow moat. Kenvue's moat is narrow — market-leading consumer-health brands (Tylenol, Listerine, Neutrogena, Band-Aid) carry real equity and shelf position, but many categories face capable private label and the brands were carved out of J&J without the parent's distribution muscle; a narrow moat supports roughly the staples average (~17x forward, where it trades), and if private-label erosion accelerates or the Tylenol litigation overhang deepens, the terminal multiple should compress toward the low-teens rather than re-rate to premium-staples levels.

Moat sources:

• Portfolio of category-leading OTC/self-care brands with decades of trust (brand-trust moat)
• Retail shelf position and pharmacy distribution inherited from J&J
• Scale in OTC regulatory approvals and clinical brand claims
• Limited pricing power vs premium staples — offset by private-label competition

Regulatory & Legal Risk

Probabilities and sensitivities are analyst estimates, not market-implied.

Scenario Macro & Key Risks

What the Market Is Pricing In

At the current price, the market pays 16.0× forward EPS, vs the house DCF terminal 14.0×, and a peer median 18.990000000000002×. The house DCF sits 26% below spot, so the market is pricing in more than the house case — roughly 2.3pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily event-driven.

Peer Quality & Weighting

Quality-weighted forward P/E: 18.9× (simple median 18.990000000000002×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $14–$22, centre $17 (-13% vs spot); spot sits at the 75th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

Reward/risk compares triangulated upside against the probability-weighted bear target, not the extreme tail. Bull case (Bull — Defensive Re-Rate): $29.

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (6.0); Revenue CAGR ±3pp (5.0); Terminal × ±15% (4.0); WACC ±1pp (2.0); Capex intensity ±15% (1.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Source Log

Citation coverage: 13/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.

Load-Bearing Assumptions

DCF: WACC 8%, terminal multiple 14×, FY+5 revenue $18B. Triangulation leans 41% on DCF, 29% on PWEV.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic sales growth < 0.01 (2 consecutive prints → staples_household). Base assumes ~4% organic growth. Sub-1% organic growth for two straight quarters would signal volume loss to private label rather than temporary softness, pulling the view toward the Consumer / Input Recession path.
• Adjusted gross margin < 0.585 (2 consecutive prints → staples_household). Sustained gross-margin erosion below the high-50s would indicate pricing power is failing to cover input and promotional costs, consistent with the mid-cycle-to-recession margin gap.
• Skin Health & Beauty segment growth < 0.0 (2 consecutive prints → staples_household). Beauty is the swing segment tied to China and travel retail. Two quarters of outright decline would remove the premium-innovation optionality that supports the Growth path.
• Net-debt / EBITDA > 3.5 (single event → staples_household). Kenvue carries ~$7.6B net debt against a covered dividend. Leverage crossing 3.5x on weaker EBITDA would pressure the payout and the defensive re-rate case.
• Trailing free cash flow < 1.6 (2 consecutive prints → staples_household). Base FCF runs ~$2.2B against ~$1.6B of dividends. Annualised FCF slipping below the dividend line would strain the cash return that anchors the mid-cycle multiple.

Fact / Inference / Speculation

• FACT: Spot $20; 52-week range $14–$22; engine rating HOLD; base-case target $18 (-7%). (source: Alpha Vantage 2026-06-26, 8 July 2026)
• INFERENCE: Triangulated FV $17 (-15% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that the market keeps paying the current multiple through the capex cycle — a regime call the engine cannot verify from fundamentals alone.

Recommendation: HOLD

Balanced: triangulated fair value $17 (-15% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple — fundamentally a multiple/regime call.

Disclosures & Limitations

This report is for informational and research purposes only. It is not personalised investment advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.

• No suitability assessment has been performed for any individual.
• Market data may be delayed or inaccurate; figures are as of the analysis date.
• Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
• Forecasts are uncertain; past performance is not indicative of future returns.
• The author or publisher may hold positions in securities mentioned.
• Users should verify information against primary sources (company filings) before acting.
• Investing involves risk of loss; there is no guarantee any target price is achieved.
• Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.